医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Notification of a New Drug Application for HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.

2018年12月17日 PM11:00
このエントリーをはてなブックマークに追加


 

MIAMI

Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, President and Chief Executive Officer (CEO): Hirotaka Nakatomi, hereinafter “Hisamitsu Pharmaceutical”), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc., announces that a New Drug Application has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of HP-3070 (asenapine) transdermal system for the treatment of schizophrenia (Development code: HP-3070, generic name: asenapine, hereinafter referred to as “the investigational product”).

The investigational product is a systemic transdermal formulation developed using Hisamitsu Pharmaceutical’s Transdermal Drug Delivery System (TDDS) technology. Hisamitsu Pharmaceutical expects the investigational product to be a new option in the treatment of schizophrenia. The development of the investigational product represents Hisamitsu Pharmaceutical’s commitment to improving the lives of the community of patients who live with schizophrenia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005053/en/

CONTACT

Stephanie Lamenta
Noven Pharmaceuticals
305-253-1916

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
  • HempFusion产品通过阿里巴巴集团的天猫国际商城进入亚洲
  • Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models
  • 天然分子のウロリチンAが筋ジストロフィーのマウスで筋機能を改善し平均余命を延長することを示す画期的な研究
  • ABEC CSR®一次性发酵罐支持Catalent扩大细胞和基因疗法产能